Ensitelvir (Xocova): The Breakthrough COVID-19 Oral Pill for Post-Exposure Prophylaxis – SCORPIO-PEP Trial Results Explained (2026)
What Is Ensitrelvir and Why Is It Making Headlines in 2026? A new oral antiviral is changing the conversation around COVID-19 prevention. Ensitelvir (brand name Xocova in Japan and Singapore) is the first oral 3CL protease inhibitor shown in a large Phase 3 trial to prevent symptomatic COVID-19 after exposure. Published in the New England Journal of Medicine on May 13, 2026, the SCORPIO-PEP trial delivered clear results: a 67% reduction in the risk of developing symptomatic, PCR-confirmed COVID-19 by day 10 compared with placebo. This isn’t another vaccine or booster. It’s a direct-acting pill you take for just 5 days after close contact with someone who tested positive — no needles, no waiting weeks for immunity to build. How Ensitrelvir Works: Immediate Antiviral Action vs. Delayed Vaccine Immunity Ensitrelvir targets the SARS-CoV-2 main protease (3CLpro or Mpro) — an enzyme the virus needs to replicate. By inhibiting this conserved protein, the pill stops viral multiplicatio...